ARGX vs BIIB vs VRTX Stock Comparison

Argenx Se, Biogen and Vertex Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
ARGX Argenx Se
$960.04 +17.3% 1M +7.7% 1Y
Market cap
$58.18B
P/E
31.0x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
5 wins
BIIB Biogen Inc.
$253.40 +8.8% 1M +53.8% 1Y
Market cap
$37.15B
P/E
106.9x
Revenue (TTM)
$10.30B
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

10 decided of 12

Argenx Se leads on 5 of the 12 questions below (Argenx Se 5, Vertex Pharmaceuticals 3, Biogen 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionARGXBIIBVRTXLeader
Larger companyMarket capitalisation $58.18B $37.15B $136.04B VRTX
Cheaper on earningsLower P/E, profitable companies only 31.0x 106.9x 34.2x ARGX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 32.8x 19.5x 30.4x BIIB
Faster revenue growthRevenue growth, trailing twelve months +61.5% +2.3% +10.5% ARGX
More profitableNet margin, trailing twelve months 32.3% 3.4% 30.7% ARGX
Better return on capitalReturn on invested capital — 1.3% — –
Less leveragedLower net debt / EBITDA — 4.5x -0.4x VRTX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +7.7% +53.8% +24.0% BIIB
Better 5-year returnAnnualised price return, 5 years +25.4%/yr -1.3%/yr +23.5%/yr ARGX
Less volatileAnnualised volatility, 1 year 37.7% 34.4% 29.5% VRTX
Higher overall scoreMean of the five percentile scores vs peers 92/100 65/100 73/100 ARGX

Percentile Scorecard

ARGXBIIBVRTX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisARGXBIIBVRTX
Valuation 82 #122 of 660 91 #60 of 660 77 #152 of 660
Growth 96 #27 of 619 27 #452 of 619 46 #333 of 619
Profitability 99 #9 of 595 88 #73 of 595 93 #40 of 595
Financial Health – 32 #466 of 683 55 #311 of 683
Shareholder Returns – 90 #48 of 459 92 #37 of 459
Overall 92 65 73
  • ARGX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • BIIB ranked among 695 companies in Pharmaceuticals and Biotechnology
  • VRTX ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodARGXBIIBVRTXSPY
1 month +17.3%+8.8%+8.0% -2.0%
3 months +12.8%+20.8%+6.5% -2.8%
6 months +20.1%+31.3%+23.3% +2.0%
Year to date +14.2%+44.0%+18.8% +10.6%
1 year +7.7%+53.8%+24.0% +12.2%
3 years +96.0%+12.5%+45.6% +68.1%
3 years, per year +25.2%+4.0%+13.3% +18.9%
5 years +210.1%-6.3%+187.6% +61.4%
5 years, per year +25.4%-1.3%+23.5% +10.1%
10 years —-20.6%+485.4% +248.5%
10 years, per year —-2.3%+19.3% +13.3%

Risk

MeasureARGXBIIBVRTXSPY
Volatility, 1Y 37.7%34.4%29.5% 13.6%
Downside volatility, 1Y 35.2%33.1%26.1% 13.9%
Beta vs S&P 500, 1Y 0.540.380.43 1.00
Return / volatility, 1Y 0.201.570.81 0.90
Max drawdown, 5Y -38.2%-64.4%-29.1% -25.4%
From 52-week high -9.3%-0.6%-3.6% -3.2%
52-week high $1,058.90$254.87$558.71 $779.14
52-week low $663.93$164.42$421.03 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleARGXBIIBVRTX
P/E now vs peer median 31.4xmedian 17.0x 107.8xmedian 17.0x 34.3xmedian 17.0x
P/S now vs peer median 10.2xmedian 8.4x 3.6xmedian 8.4x 10.5xmedian 8.4x
EV/EBITDA now vs peer median —median 14.6x 32.7xmedian 14.6x 29.7xmedian 14.6x
P/FCF now vs peer median —median 19.0x 18.1xmedian 19.0x 42.6xmedian 19.0x
P/B now vs peer median —median 2.0x 2.0xmedian 2.0x 6.5xmedian 2.0x
PEG now vs peer median 0.30median 0.43 -2.80median 0.43 6.39median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsARGXBIIBVRTX
Revenue $5.82B $10.30B $12.95B
Gross profit $5.24B $7.62B $11.08B
Operating income $1.74B $445.10M $4.30B
Net income $1.88B $347.50M $3.98B
Free cash flow – $2.07B $3.20B
R&D $1.80B $2.15B $4.25B
EPS (diluted) $28.43 $2.35 $15.58
Cash & equivalents – $1.30B $4.98B
Total debt – $7.29B $4.50B
Shares (diluted) 66.03M 147.80M 255.20M
Enterprise value $58.18B $26.46B $103.77B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricARGXBIIBVRTX
P/E 31.4x 107.8x 34.3x
P/FCF – 18.1x 42.6x
P/Operating cash flow – 16.7x 37.0x
P/S 10.2x 3.6x 10.5x
P/B – 2.0x 6.5x
P/Tangible book – 6.8x 11.0x
EV/EBITDA – 32.7x 29.7x
EV/EBIT 34.1x 97.6x 31.3x
EV/Revenue 10.2x 4.2x 10.4x
EV/FCF – 21.0x 42.1x
EV/Operating cash flow – 19.3x 36.5x
PEG (3Y EPS CAGR) 0.30 -2.80 6.39

Growth

14 metrics
MetricARGXBIIBVRTX
Revenue growth (1Y) 61.5% 2.3% 10.5%
Revenue CAGR (3Y) 80.5% 1.0% 10.3%
Gross profit growth (1Y) 62.2% 0.6% 9.5%
Gross profit CAGR (3Y) 80.0% 0.5% 9.3%
Operating income growth (1Y) 120.6% -76.6% 7.8%
Operating income CAGR (3Y) 85.1% -34.8% 3.5%
Net income growth (1Y) 22.5% -78.4% 8.2%
Net income CAGR (3Y) 115.5% -38.1% 4.6%
EPS growth (1Y) 20.9% -78.5% 9.2%
EPS CAGR (3Y) 104.8% -38.5% 5.4%
Operating cash flow growth (1Y) – -8.4% -0.6%
Operating cash flow CAGR (3Y) – 18.2% -5.5%
Free cash flow growth (1Y) – -10.1% -4.0%
Free cash flow CAGR (3Y) – 24.9% -8.7%

Profitability

14 metrics
MetricARGXBIIBVRTX
Gross margin 90.0% 74.0% 85.5%
EBITDA margin – 12.9% 35.1%
Operating margin 29.9% 4.3% 33.2%
Pretax margin 32.6% 4.3% 36.7%
Net margin 32.3% 3.4% 30.7%
FCF margin – 20.1% 24.7%
Operating cash flow margin – 21.8% 28.5%
Return on equity – 1.8% 19.3%
Return on assets – 1.1% 13.2%
Return on invested capital – 1.3% –
Return on capital employed – 1.6% 17.2%
Asset turnover – 0.3x 0.4x
Cash conversion (OCF / net income) – 6.5x 0.9x
Stock comp / revenue – 2.9% 5.2%

Financial Health

11 metrics
MetricARGXBIIBVRTX
Debt / assets – 22.7% 13.7%
Debt / equity – 0.4x 0.2x
Net debt / EBITDA – 4.5x -0.4x
Debt / FCF – 3.5x 1.4x
Liabilities / assets – 41.0% 36.1%
Equity / assets – 59.0% 63.9%
Interest coverage 10,120x – 93.0x
Current ratio – 1.9x 2.3x
Quick ratio – 0.9x 1.7x
Cash ratio – 0.3x 1.3x
Altman Z-score – 3.13 8.70

Shareholder Returns

7 metrics
MetricARGXBIIBVRTX
Dividend yield – – –
Net buyback yield – 0.1% 0.7%
Shareholder yield – 0.1% 0.7%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusARGXBIIBVRTX
Forward P/E 32.8xFY2026 19.5xFY2026 30.4xFY2026
EPS, next fiscal year $29.27FY2026 $12.97FY2026 $17.71FY2026
EPS growth, next FY +49.6%FY2026 -15.1%FY2026 -3.7%FY2026
EPS growth, the year after +32.0% +33.4% +20.2%
Revenue, next fiscal year $6.16BFY2026 $10.09BFY2026 $12.68BFY2026
Revenue growth, next FY +44.9%FY2026 +2.1%FY2026 +5.9%FY2026
Revenue growth, the year after +24.0% +11.5% +19.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersARGXBIIBVRTX
Held by institutions 46.1% 96.4% 95.1%
Institutions holding 506 1,038 1,747
Change in shares held, QoQ -2.0% +6.0% +3.9%
Institutions buying 263 549 904
Institutions selling 162 294 605
Buyers to sellers 1.62 1.87 1.49

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ARGXBIIBVRTX
ARGX 1.00 0.23 0.34
BIIB 0.23 1.00 0.48
VRTX 0.34 0.48 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ARGX, BIIB and VRTX?

Vertex Pharmaceuticals (VRTX) is the largest by market capitalisation: Argenx Se (ARGX) $58.18B, Biogen (BIIB) $37.15B, Vertex Pharmaceuticals (VRTX) $136.04B.

Which stock is cheaper, ARGX, BIIB and VRTX?

Argenx Se (ARGX) trades on the lowest price-to-earnings ratio (Argenx Se (ARGX) 31.0x, Biogen (BIIB) 106.9x, Vertex Pharmaceuticals (VRTX) 34.2x). On next year's consensus earnings, Biogen (BIIB) is cheapest (Argenx Se (ARGX) 32.8x, Biogen (BIIB) 19.5x, Vertex Pharmaceuticals (VRTX) 30.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Argenx Se (ARGX) grew revenue fastest over the trailing twelve months: Argenx Se (ARGX) +61.5%, Biogen (BIIB) +2.3%, Vertex Pharmaceuticals (VRTX) +10.5%.

Which company is more profitable?

Argenx Se (ARGX) has the highest net margin (Argenx Se (ARGX) 32.3%, Biogen (BIIB) 3.4%, Vertex Pharmaceuticals (VRTX) 30.7%).

Which stock has performed better?

Over the past year Biogen (BIIB) returned the most: Argenx Se (ARGX) +7.7%, Biogen (BIIB) +53.8%, Vertex Pharmaceuticals (VRTX) +24.0%. Over five years, Argenx Se (ARGX) compounded fastest (Argenx Se (ARGX) +25.4%/yr, Biogen (BIIB) -1.3%/yr, Vertex Pharmaceuticals (VRTX) +23.5%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Vertex Pharmaceuticals (VRTX) has been the steadiest (Argenx Se (ARGX) 37.7%, Biogen (BIIB) 34.4%, Vertex Pharmaceuticals (VRTX) 29.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ARGX, BIIB and VRTX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Argenx Se (ARGX) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.